Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291807 | 0.88 | KMT2A (0.48) | KMT2AMAPK1SYKCYP3A4ACHE | |
| SCHEMBL6274032 | 0.85 | ACHE (0.45) | MAPK1SYKCYP3A4JAK3ACHE | |
| Hydrochloric Acid SCHEMBL6273972 | 0.84 | ACHE (0.47) | MAPK1SYKCYP3A4JAK3ACHE | |
| SCHEMBL13242865 | 0.83 | ACHE (0.43) | ACHECD274PDCD1LG2TSHRCCR5 | |
| SCHEMBL13242867 | 0.83 | ACHE (0.43) | ACHECD274PDCD1LG2TSHRCCR5 | |
| SCHEMBL6347933 | 0.82 | KDM4E (0.42) | MAPK1SYKCYP3A4JAK3ACHE | |
| Hydrochloric Acid SCHEMBL6347620 | 0.81 | ACHE (0.43) | MAPK1SYKCYP3A4JAK3ACHE | |
| SCHEMBL3399889 | 0.81 | KMT2A (0.45) | KMT2AMAPK1ACHECD274PDCD1 | |
| SCHEMBL4285309 | 0.81 | KMT2A (0.45) | KMT2AMAPK1ACHEMEN1KDM4E | |
| SCHEMBL3401722 | 0.80 | MAPK1 (0.40) | KMT2AMAPK1SYKCYP3A4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | KMT2A 1885/4885MAPK1 13/4885SYK 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.